| Eyes | 38 | 36 | 38 | – |
| Age (years) | 45.2 ± 10.8 | 41.9 ± 11.7 | 47.6 ± 6.5 | 0.174* |
| Sex, Male/Female | 19/19 | 12/11 | 11/10 | 0.979† |
| Spherical Equivalent (D) | −0.12 ± 0.95 | −0.22 ± 0.66 | −0.32 ± 0.63 | 0.521* |
| Intraocular Pressure (mmHg) | 14.4 ± 2.3 | 16.1 ± 3.2 | 19.0 ± 6.9 | < 0.001* |
| Axial Length (mm) | 23.5 ± 0.9 | 23.3 ± 1.0 | 23.3 ± 0.8 | 0.520* |
| Best Corrected Visual Acuity (logMAR) | 0.00 ± 0.01 | 0.00 ± 0.01 | 0.15 ± 0.37 | 0.005* |
| Exophthalmometry (mm) | – | 17.94 ± 1.90 | 18.58 ± 2.38 | 0.228‡ |
| Mean Defect of Visual Field (dB) | – | −0.29 ± 0.54 | −6.79 ± 3.91 | < 0.001‡ |
| Clinical Activity Scoring | NA | 1.08 ± 1.18 | 1.73 ± 1.12 | 0.019‡ |
| Duration of Graves’ Disease (yrs) | NA | 4.78 ± 7.03 | 3.20 ± 3.44 | 0.356‡ |
| History of smoking | – | 4/23 | 7/21 | 0.192† |
| Free Triiodothyronine (pg/ml) | – | 7.13 ± 6.41 | 6.25 ± 4.76 | 0.192‡ |
| Free Thyroxine (ng/dl) | – | 3.41 ± 3.15 | 3.61 ± 5.51 | 0.389‡ |
| Thyroid-Stimulating Hormone (μIU/ml) | – | 7.21 ± 19.01 | 1.01 ± 1.37 | 0.023‡ |
